Oral therapy of staphylococcal infection of orthopaedic implants with 900 mg/day rifampicin combined with either 1.5 g/day fusidic acid for 5 days followed by 1 g/day thereafter, or 600 mg/day ofloxacin was compared. Patients with an infected hip were treated for 6 months, with removal of any unstable prosthesis after 5 months' treatment and those with an infected knee prosthesis were treated for 9 months, with removal of the prosthesis after 6 months of treatment. Patients with infections of other type of bone implants were treated for 6 months with removal of the implant after 3 months of treatment, if necessary. Cure was defined as the absence of clinical, microbiological and radiological evidence of infection 12 months after completion of treatment. The treatment of 46 of the 52 included in the study was evaluated for safety and that of 42 was assessed for efficacy. Overall treatment was successful for 11 (55%) of 20 patients treated with rifampicin and fusidic acid group and for 11 (50%) of the 22 treated with rifampicin and ofloxacin. Treatment failed in four cases in each treatment group because of persistent infection. One patient given rifampicin and fusidic acid and three patients given rifampicin and ofloxacin failed treatment because of relapse. Superinfection led to failure in the remainder and was due to staphylococci in all but one case in which Acinetobacter calcoaceticus var. anitratus was isolated. There were no side effects related to study treatment. Oral treatment with rifampicin combined with fusidic acid may be a suitable alternative to the combination of rifampicin and ofloxacin for treating implant infections due to Staphylococcus spp. either when the patient is intolerant to quinolones or when the infecting organism is resistant to these drugs.
Introduction
Mechanical dysfunction, thromboembolic disease and infection are the three major complications of orthopaedic surgery. Infection rates are of 0.5-2% depending upon the type of surgery, 1,2 with rates following hip and knee arthroplasty of 0.5% and 1%, 2, 3 respectively. With the increase in the number of hip and knee replacements over the past 10 years in developed countries, the number of patients infected has risen, with Staphylococcus aureus and coagulase-negative staphylococci accounting for 45-55% of all infections regardless of the type of implant. 4 Conventional treatment of post-surgical infection includes long-term intravenous antibiotic therapy with a one-or two-stage replacement of the infected implant which requires the patient to remain immobilized in hospital.
In an earlier open study, we found that the oral regimen of rifampicin and ofloxacin cured 74% of implant infections due to staphylococci, 5 rates which were comparable to those achieved with conventional therapy. This regimen therefore became our first-line regimen for treating staphylococcal implant infections. Meanwhile, resistance to the quinolones has dramatically increased among nosocomial isolates of staphylococci and now averages 35% in our hospital. We therefore sought an alternative regimen. Fusidic acid is one of the few oral drugs that is still effective against oxacillin-resistant, quinolone-resistant staphylococci. 6 MICs of fusidic acid in vitro are 0.03-0.25 mg/L for S. aureus 7 , 8 and S t a p h y l o c o c c u s epidermidis. 9 The intracellular concentration of the drug in human polymorphonuclear leucocytes and lymphocytes is seven-to tenfold greater than that found extracellularly 10 although there is little evidence of accumulation in other cells.
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When given for prolonged periods, fusidic acid should be given in combination with another antistaphylococcal antibiotic such as rifampicin or a fluoroquinolone to prevent the development of resistance. 12 Fusidic acid has been investigated for its potential in managing orthopaedic infections in small, open studies which have included patients infected with various microorganisms; [13] [14] [15] in one study of implant infection caused by coagulase-negative staphylococci, treatment with fusidic acid alone or in combination with a -lactam was successful in nine of 11 patients without removal of the implant. 13 Since there have been no controlled studies we undertook a trial to compare rifampicin combined with either fusidic acid or ofloxacin for the treatment of staphylococcal implant infections.
Patients and methods
Inclusion of patients
Patients were eligible for inclusion when there was clinical and radiological evidence of an orthopaedic implant infection (as previously reported 5 ) pro-vided that treatment with rifampicin, ofloxacin and fusidic acid was not contraindicated. Pain around the joint was considered evidence of infection as were fistulas or loosening of the joint when identified radiographically using the contrast agent Hexabrix 320 (Laboratoire Geurbet, Aulnay sous Bois, France)
At the time of inclusion, demographic and clinical data were recorded, as were laboratory data, including differential blood counts, hepatic enzyme levels, the erythrocyte sedimentation rate, C-reactive protein level and radiological data.
Each patient gave informed consent and had to be available for follow-up for 12 months after completing treatment. The protocol was approved by the local ethics committee.
Bacteriological confirmation
When available, pus was sampled by using a compress or a swab; otherwise material was obtained by needle aspiration of the implant or by surgical biopsy after three consecutive aspirations had remained sterile.
Specimens of pus were stained with Gram's stain and examined microscopically for the presence of polymorphonuclear leucocytes and Gram-positive cocci. Approximately 200 L of material was cultured on trypticase soy agar, Columbia agar containing 5% sheep blood, brain heart infusion broth and Schaedler broth (bio-Mérieux, Marcy l'Etoile, France) and the media were incubated at 37°C aerobically, in enriched CO 2 and anaerobically. 16 Bacteria were identified by the appearance of the colonies, the presence of haemolysis, their Gram reaction, the production of catalase and coagulase and by their biochemical reactions and antibiogram in a commercial kit (AutoSCAN-4, Baxter Diagnostics Inc., Deerfield, IL, USA). The susceptibility to rifampicin, fusidic acid and ofloxacin was determined by a dilution method for determining the MIC. Infection was confirmed by recovery of an organism from a joint aspirate or a surgical bone biopsy specimen whereas isolation of an organism with the same biotype and susceptibility to -lactam a n t ibiotics, co-trimoxazole, gentamicin, erythromycin, doxycycline, teicoplanin, vancomycin, fosfomycin, rifampicin, fusidic acid and ofloxacin had to be recovered at least twice from the discharge of a fistula.
Treatment
Each patient was assigned to their treatment regimen according to their year of birth, with those born in odd years receiving an oral regimen of rifampicin 900 mg od together with fusidic acid 500 mg tds for 5 days followed by 500 mg bd and those born in even years receiving an oral regimen of rifampicin 900 mg od together with ofloxacin 200 mg tds. Patients with an infected hip implant were treated for a total of 6 months. When the prosthesis was unstable, it was replaced with a new implant in a one-stage process after 5 months of antibiotic treatment. Patients with an infected knee implant were treated for 6 months before and 3 months after one-or two-stage removal and re-implantation of the prosthesis. Patients with infected osteosynthesis devices were treated for 6 months, the foreign body was removed and treatment was continued for a further 3 months, if necessary.
Follow-up
Clinical progress was followed up monthly and laboratory tests including blood and differential counts, erythrocyte sedimentation rate and hepatic enzyme levels were repeated every 3 months. Further specimens were only obtained for culture when there was failure or relapse. Patients were examined at least once during the first 12 months after completing treatment and yearly thereafter, unless this was not possible in which case a telephone interview took place which included questions about the use of analgesics, pain and signs of dysfunction and any physical examination or radiological evaluation by another surgeon or doctor.
Outcome of treatment
Treatment was deemed to have failed when there was any clinical, radiological or microbiological evidence of infection. In cases of treatment failure, the evaluation procedure included a check for the patient's compliance by interview and the colour of freshly voided urine, conventional radiography and fistulography. In addition, a specimen was obtained from the site of infection by puncture or biopsy for culture as described above and the antibiotic activity was determined by bioassay using Micrococcus luteus and a susceptible strain of S. epidermidis. The antibiotic activity of the patient's urine was also assayed in the same way. 16 Relapse was defined by the reappearance after eradication of an isolate of Staphylococcus spp. which shared the same biotype and antibiogram as the original isolate.
Statistics
The statistical analysis was performed using Fisher's exact test.
Results
Fifty-two patients entered the study between January 1990 and July 1992. The treatment of five of the 28 patients who had been assigned treatment with rifampicin and fusidic acid and the treatment of one of the 24 patients allocated to receive rifampicin and ofloxacin could not be evaluated as the cases were lost to follow-up.
The two study groups did not differ significantly with respect to sex, age, or type of infected implant or in the proportion of infections due to S. aureus (Table I) . Twenty patients had an infected hip prosthesis. Twentyeight patients had an infection due to S. aureus; of these, one was mixed with two strains of corynebacteria, and one with a coagulase-negative staphylococcus. The remainder had infections due to coagulase-negative staphylococci (Table II) . Fistulas were present in 19 of 46 (41%) patients. The microbiological diagnosis was based on the pus discharged from the fistula in 18 (39%) patients, after puncture of the infected site in 18 (39%) patients, and after surgical biopsy of the infected site in 10 (22%) patients. The time interval between surgery and laboratory confirmation of infection ranged from 1 month to 6.7 years and was not statistically different between those treated with rifampicin and fusidic acid and those treated with rifampicin and ofloxacin.
Clinical outcome
The treatment of four patients was unassessable. One patient (number 118) treated with rifampicin and fusidic acid died of a cardiac arrest due to a myocardial infarction after 5 months of treatment and another patient (number 304) stopped treatment after 2 weeks because of vomiting and other gastrointestinal side effects. One patient treated with rifampicin and fusidic acid (number 201) and another given the alternative regimen (number 108) stopped the treatment voluntarily after 2 months. Thus, the treatment of 20 patients given rifampicin and (Table II) . Treatment failure led to the decision to remove the orthopaedic device from one patient treated with rifampicin and fusidic acid and from four patients treated with the alternative regimen. Mechanical dysfunction resulted in removal of the devices from another nine patients. Six of 14 patients (43%) in whom the implant was removed were cured. Fourteen of 25 (56%) patients with S. aureus infection were cured, of whom four had their device removed and eight of 17 (47%) patients with coagulase-negative staphylococci were cured although 14 prostheses were removed.
237
Treatment of infection of knee prostheses was least successful, with only three of nine patients (33%) being cured (Table III ) and the success rate for an infected hip prosthesis was only a little better with seven of 17 patients (41%) responding whereas 12 of 16 patients (75%) with other infections were cured. In all, 16 (57%) patients were cured without removal of the prosthesis. There was no evidence that poor compliance resulted in failure but this was related to inadequate drug concentrations (data not shown).
Microbiological outcome
Two patients treated with fusidic acid and rifampicin and five of those treated with the alternative regimen declined further exploration, so were not followed up bacteriologically.
No follow-up cultures were available from one of the eight patients who failed to respond to treatment with fusidic acid and rifampicin. One of the patients failed treatment because of a superinfection with Acinetobacter calcoaceticus var. anitratus and two because of infection with new isolates of coagulase-negative staphylococci that were resistant to rifampicin but susceptible to both fusidic acid and ofloxacin. The remaining four failures of treatment with fusidic acid and rifampicin were due to persistence as none of the patients showed any improvement. Two of the isolates were S. aureus; one of these was resistant to both rifampicin and ofloxacin but susceptible to fusidic acid while the other was susceptible to all three antimicrobial agents. The other two isolates were coagulase-negative staphylococci, one of which was resistant to rifampicin but susceptible to both fusidic acid and ofloxacin.
Five of the eight patients who failed to respond to rifampicin and ofloxacin were lost to follow-up. Two of the failures of treatment were due to new isolates of coagulase-negative staphylococci that were resistant to both agents as well as to fusidic acid and the remaining four cases were due to persistence, due in two cases to S. aureus resistant to rifampicin but susceptible to both ofloxacin and fusidic acid and in two cases to coagulasenegative staphylococci resistant to all three agents. 
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Adverse events
No adverse events related to the study regimens were reported.
Discussion
We report the results of a trial of an oral regimen of rifampicin combined with either fusidic acid or ofloxacin for treating orthopaedic implants infected with staphylococci. Both regimens were similarly effective and safe, regardless of the type of implant, and the combined regimen of rifampicin and ofloxacin was as effective as before. 5 No statistically significant difference in outcome was found between the two study regimens but the small size of each group does not preclude the possibility that a difference does, in fact, exist.
Rifampicin-resistant staphylococci were responsible for all but two of the failures and one of the six staphylococci isolated after treatment with rifampicin and fusidic acid was resistant to the latter drug whereas five of the six staphylococci isolated after treatment with rifampicin and ofloxacin were resistant to the quinolone. However, molecular biology techniques such as pulsed-field gel electrophoresis would be needed to distinguish between an original isolate that had become resistant during treatment and the acquisition of a new isolate that was already resistant. These results might be explained by a failure to detect polymicrobial infections and those due to different strains of coagulase-negative staphylococci. The selection of staphylococci resistant to both rifampicin and ofloxacin from the infected implants of those treated with these drugs suggests that resistance to these two agents might not be independent since rifampicin-resistant staphylococci were more prevalent among those that were also resistant to fluoroquinolones than among those that were susceptible. In contrast, the selection of staphylococci resistant to rifampicin but susceptible to fusidic acid among those treated with this regimen indicates that resistance mechanisms are independent. Indeed, in-vitro studies have shown that the combination of fusidic acid with rifampicin prevents the selection of staphylococci resistant to either drug. 17 Rifampicin-resistant staphylococci have emerged during treatment with a combination of rifampicin and fusidic acid. 18 We observed similar results in the present study, but these might have been a result of reducing the dosage after 5 days so that fusidic acid did not reach effective concentration in situ. In retrospect, it was probably not necessary to lower the dose of fusidic acid, since 1.5 g/day is well tolerated 19 and maintaining this dose throughout combined treatment with rifampicin might result in a higher cure rate than we achieved in the present study.
In conclusion, the results of this study suggest that a regimen of fusidic acid and rifampicin offers an alternative to the combination of ofloxacin plus rifampicin for the oral treatment of staphylococcal orthopaedic device infection either when the patient is intolerant to quinolones or when the infecting Staphylococcus spp. is resistant to these drugs. 
